Cardiology
18 November, 2026
J Am Heart Assoc. 2026 Nov 18:e049175. doi: 10.1161/JAHA.126.049175. Online ahead of print.
ABSTRACT
BACKGROUND: Endothelial dysfunction is a hallmark of cardiovascular disease, driven by oxidative stress, inflammation, and platelet activation. We hypothesized that the FXa inhibitor rivaroxaban, alone or combined with clopidogrel, could counteract platelet-induced oxidative injury to the endothelium and preserve endothelial function.
METHODS: We conducted a prospective multicenter cohort clinical study in patients on chronic antiplatelet therapy (mostly aspirin) who initiated rivaroxaban, measuring indices of oxidative stress, endothelial function (nitric oxide bioavailability, ICAM-1/VCAM-1 levels), and platelet activation before and after rivaroxaban. In parallel, human endothelial cells were exposed to convulxin-activated platelet supernatants from healthy donors with or without rivaroxaban±clopidogrel, and assessed for NOX2 expression/activity, adhesion molecules, nitric oxide (NO) production, and tube-forming capacity. An ex vivo mouse model of angiotensin II-induced endothelial dysfunction was used to evaluate vascular relaxation responses after incubation with rivaroxaban and/or clopidogrel.
RESULTS: Rivaroxaban significantly improved endothelial function in patients and in vitro, as shown by reduced endothelial ICAM-1 and VCAM-1 expression and increased NO availability despite platelet-derived oxidative stress. Rivaroxaban also decreased H2O2 production, downregulated endothelial NOX2 expression and sNOX2-dp release, and restored angiogenic capacity in endothelial cells exposed to activated platelets. Clopidogrel alone had negligible effects on these parameters. Notably, adding clopidogrel to rivaroxaban provided no additional endothelial benefit beyond rivaroxaban monotherapy. In an ex vivo hypertensive vessel model, rivaroxaban (but not clopidogrel) markedly improved endothelium-dependent relaxation.
CONCLUSIONS: Rivaroxaban effectively preserves endothelial function by inhibiting platelet-induced NOX2-mediated oxidative stress and inflammation. The lack of any additive benefit from clopidogrel suggests that rivaroxaban alone may be mechanistically sufficient to counteract platelet-driven endothelial dysfunction. These findings reveal a novel vasoprotective mechanism for rivaroxaban and underscore its potential clinical value in mitigating vascular injury beyond its established antithrombotic effects.
PMID:43048771 | DOI:10.1161/JAHA.126.049175
European Heart Journal
© 2026 Imedsource, All Rights Reserved
For unrestricted access to content and a seamless experience,
Complete your profile to help us deliver a more personalized experience.